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cipients are lacking.
Methods: We evaluated characteristics, diagnostic results,
management and outcomes of all inﬂuenza A infections
(pandemic H1N1 versus SFlu) and determined the risk fac-
tors associated with pneumonia and all-cause mortality in
HM patient and HSCT recipients at MD Anderson Cancer
Center (MDACC) from April 2009 to July 2013.
Results: A total of 259 patients were identiﬁed, including 134
(52%) HMpatients and 125 (48%) HSCT recipients. Majority of
patients (242, 93%) were adults, males (147, 57%) with un-
derlying diseases in remission (160, 64%). About half of pa-
tients required hospitalization for outcomes including
pneumonia 28% (72 pts) and death 6% (16 pts). Majority of
patients (214, 83%) received antiviral therapy within a me-
dian of 3 days (range, 0d e 28d) after onset of ﬁrst symptom.
Compared to HCT recipients, a signiﬁcantly higher percent-
age of HM pts were in active stages of cancer with severe
neutropenia (26, 20%) and severe lymphopenia (25, 19%) and
required hospitalization (76, 57%). Multivariable logistic
regression analysis identiﬁed hematologic malignancy (AOR:
2.5 (95% CI: 1.2, 5.28), decreased albumin (AOR: 2.2 (95% CI:
1.0, 4.64), and delay in initiation of antiviral therapy (AOR:
1.3 (95% CI: 1.12, 1.47) as signiﬁcant risk factors for devel-
opment of pneumonia (P¼ 0.05), after adjusting for the virus
strain. Interestingly, H1N1 infections were more prevalent in
Hispanic population (26, 31%) and requiredmore mechanical
ventilation (9, 11%) compared to SFlu, but no signiﬁcant dif-
ferences were observed with respect to pneumonia or mor-
tality between these two viruses.
Conclusions: Inﬂuenza remains a signiﬁcant cause of
morbidity and mortality in HM patients and HSCT recipients.
Compared to HCT recipients, HM patients weremore likely to
progress to pneumonia, probably owing to active cancer
stage and pancytopenia. H1N1 patients did not have higher
mortality rate compared to SFlu in either of the groups. Early
antiviral therapy remains crucial in preventing morbidity in
this population.395
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Background: Thalassemia syndromes are very prevalent in
many parts of the world including Asia. Allogeneic hemato-
poietic cell transplantation (HCT) is the only curative therapy
accepted worldwide.
Objectives: To assess outcomes of HCT for thalassemias and
hemoglobinopathies in single medical center in Thailand.
Methods: Case series study for thalassemia and hemoglo-
binopathy patients undergoing HCT at Bangkok Hospital
Medical Center from February 2009 thru October 2013.
Results: Therewere totally 14 patients. 10 cases were Thais, 1
was French-Thai, 1 was Bangladeshi, 1 was Lao, and 1 was
Omani who had sickle cell disease (SCD). 12 cases were
diagnosed as beta-thalassemia/hemoglobin E diseases, 1 as
transfusion-dependent alpha-thalassemia, and 1 as SCD.
Among 14 HCTs, 9 patients underwent bone marrow trans-
plant (BMT), 4 patients underwent umbilical cord blood
transplant (CBT), and 1 patient underwent combined cordblood and marrow transplantation. All 14 related donors
were fully-HLA-matched, 4 had normal typing, 9 had thal-
assemia trait, and 1 had sickle cell trait. Male to female pa-
tients ratiowere 11:3. Patients’ ages at transplant varied from
2 years to 15 years 11 months with median of 4 years 10
months. Patient’s body weight varied from 11.1 to 50 kilo-
gram (median 17.2 kilogram). According to Pesaro classiﬁ-
cation, among 13 thalassemia patients there were 8 class I,
and 5 class II patients. Busulfan, ﬂudarabine, and rabbit ATG
were mainly used as myeloablative conditioning regimen.
Cyclosporine and short-course methotrexate were mainly
used as graft-versus-host disease (GvHD) prophylaxis in BMT
group, while cyclosporine alone was used in CBT group.
CD34+ cell doses per kilogram body weight recipients were
ranged from 5.6 to 34.7x106 (median 11.3x106) in BMT group
(n¼9), and from 1.6 to 3x105 (median 2.3x105) in CBT group
(n¼4). Complete donor engraftments were achieved in 11
patients. Mixed-chimerism states with donor predominance
were present in 2 patients from BMT and 1 patient from CBT
group. No patients experienced graft failure. Neutrophil re-
coveries were evident on days +10 to +23 (median day +14),
and platelet recoveries were observed on days +19 to +64
(median day +40). 2 patients had mild veno-occlusive dis-
eases and were later completely reversible. No patients
developed acute or chronic GvHD. Therewere no mortalities.
1 patient had treatable pneumocystis pneumonia at 4
months post CBT. Median follow-up time for all patients was
2 years (1 month to 4 years 8 months). Overall (OS) and
disease-free survival (DFS) were 100% and 100% for all pa-
tients (n¼14). Based on risk class, the OS and DFS for class I
thalassemia patients (n¼9) were 100% and 100%, and class II
patients (n¼4) were 100% and 100%, respectively.
Conclusions: Our experiences in HCT for thalassemias and
hemoglobinopathies were very favorable. Regular follow-up
visits are encouraged to determine long term outcomes.396
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We developed a 2 step haploidentical HSCT where 76 pa-
tients received myeloablative or reduced intensity regimens
followed by a DLI containing a ﬁxed dose of 2.0 x 108/kg T
cells (HSCT step 1). After 2 days, 60mg/kg/d x 2 of CY was
infused, followed a day later by a CD34 selected PBSC product
[HSCT step 2 median dose 5 x 106/kg (range 1.64-10)]. We
concurrently used a 1 step HSCT approach in a group of 16
patients, 8 with unrelated donors (URD) and 8 patients (6
with haploidentical, 2 with matched related donors) with
comorbidities precluding eligibility for the 2 step protocol.
The 1 step patients were given the same conditioning, but
afterwards received unmanipulated PBSC’s [median CD 34
dose 7.18x106/kg, (range 4.41-10); median T cell dose 2.9 x
108/kg, (range 1.4-3.90)]. CY 60mg/kg/d x 2 was infused 48
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occurs only in the 2 step approach, we compared engraft-
ment rates and IR between the 2 groups. All 92 patients had
good risk disease. In the 1 step vs the 2 step study, median
time to ANC > 500/ul was 19(range 15-28 days) vs 11[range
9-16 days (p¼0.000-Mann-Whitney)], and for platelets
> 20,000/ul, 29(range 18-52 days) vs 17(range 12-173 days)
respectively (ns). The signiﬁcant difference in time to ANC
recovery in the 1 step group was possibly from the exposure
of the donor PBSC’s to CY. When we accounted for the later
occurrence of day 0 in the 2 step group, the median time to
ANC recovery was still 3 days longer in the 1 step group even
though this group received a higher median CD 34 dose.
Possibly due to the earlier count recovery in the 2-step group,
the median CD3/4 count at day 28 was 20(range 5-50/ul) in
the 1 step group vs 54(range 11-299/ul) in the 2 step group.
By day 90, differences between the groups resolved, with a
median CD3/4 count of 157(range 29-397/ul) vs 147(range
10-814/ul) in the 1 and 2 step groups respectively. Median
CD3/8 count at day 28 was 40 (range 3-157/ul) vs 57 (range
4-2682/ul) and at day 90 was 239(range 12-1439/ul) vs
204(range 2-2379/ul) in the 1 and 2 step groups respectively.
The percentages of patients on steroids for GVHD at day 28
(13% in the 1 step group vs 31%) and 90 (18% vs 33%) was not
signiﬁcantly different between the two groups (p¼0.215 and
0.413 respectively, Pearson Chi Square). Themedian length of
stay (LOS) was 41(range 15-99 days) vs 32(range 15-156
days) in the 1 and 2 step groups respectively. The 2 step
approach to HSCT allows for the administration of a ﬁxed
dose of T cells from which to optimize outcomes and cir-
cumvents exposure of donor cells to the effects of CY. Our
experience with a 1 step approach suggests later ANC re-
covery and possibly initial T cell recovery versus the 2 step
approach. There may be a slightly longer LOS in the 1 step
group possibly from longer time to count recovery. Formal
analyses of the differences between the two approaches will
be performed when more patients are treated at our insti-
tution with the 1 step approach.Table 1
Patient characteristics comparing cases and controls
Cases (n¼5) Controls (n¼15) P value
Age (Median with range) 43 (21-68) 47 (27-71) 0.646
Male gender 5 (100%) 13 (86.7%) 1.000
Type of transplant
Allogeneic e Related,
Unmatched
0 (0%) 3 (20%) 0.539
Allogeneic e Unrelated,
Matched
3 (60%) 2 (13.3%) 0.073
Allogeneic e Unrelated,
Unmatched
1 (20%) 7 (46.7%) 0.603
Autologous 1 (20%) 3 (20%) 1.000
Immunosuppressive therapy on day + 14
Tacrolimus 4 (80%) 11 (73.3%) 1.000
Corticosteroids 0 (0%) 1 (6.7%) 1.000
Mycophenolate 1 (20%) 2 (13.3%) 1.000
GvHD 3 (60%) 2 (13.3%) 0.073
WBC 4.1 (0.2-9) 4.7 (0.8-9.2) 0.668
ANC 3.0 (0.7-5.3) 3.2 (0.1-9.3) 0.882
Hemoglobin 8.7 (6.8-10) 10.7(7.2-14) 0.066
Platelets 70 (7-165) 120 (35-236) 0.147
Cr 1.25 (0.83-1.97) 0.84 (0.38-1.29) 0.081
Alk Phos 85 (36-138) 69 (50-95) 0.243
Total bilirubin 1.2 (0.6-2) 0.6 (0.3-0.9 0.003
ALT 71(10-151) 29 (8-71) 0.026
Albumin 2.6(2.2-3.1) 3.7 (2.7-4.2) < 0.001397
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Introduction: HHV6 (Human Herpes Virus 6) reactivation
occurs in approximately one-half of patients following allo-
geneic hematopoietic stem cell transplant (HSCT). The target
tissues of HHV6 and the extent to which HHV6 causes dis-
ease in those with viremia is not resolved.
Methods: Biopsies or body ﬂuid sampling are routinely
performed at our center to determine the cause of otherwise
unexplained end-organ disease. We describe 14 pediatric
HSCT patients who were found with HHV6 PCR end-organ
tissue positivity on these studies. Of these 14 patients, 13 had
received myeloablative conditioning, 12 had received an
unrelated donor graft, 10 had underlying malignant disease,
9 patients had acute GVHD, and 3 were diagnosed with
chronic GVHD.
Results: Robust statistical partitioning identiﬁed two distinct
subgroups within this population based on the highest HHV6
viral load in blood. In 10 of the 14 patients, a peak blood viralload (>28,000 copies/mL) occurred developed while the
other 4 patients had peak blood viral loads<2000 copies/ml.
All patients received antiviral treatment to treat their
viremia. At the time of biopsy and/or ﬂuid sampling, only 1
patient out of 14 had a blood viral load >28,000 copies/mL
and the remainder had very low (<1500 copies/ml) or un-
detectable HHV6 virus in the blood despite having detectable
virus in their tissues. In total, 8/14 patients biopsied patients
who had tissue/body ﬂuid viral positivity did not have con-
current detectable virus in blood, in 5/14, the blood viral load
was <1500 copies/ml, while only in one patient who had
encephalitis there was a high copy number of 344,488
copies/ml detected in blood at the time of detection of the
virus in the cerebrospinal ﬂuid (CSF).
HHV6was found in CSF (3 patients), BAL ﬂuid (3 patients),
GI tract (5 patients), bone marrow (5 patients), pericardial
ﬂuid (3 patients), liver (1 patient), and gallbladder (2 pa-
tients). Statistical analysis showed no difference between the
two subgroups with respect to age, gender, stem cell graft,
stem cell donor, HLA compatibility between the donor and
the recipient, acute/chronic graft-versus-host disease, or
survival. Of note, 4 out of 14 patients had co-existent CMV
viremia. There was a decreasing linear trend (Cochran-
Armitage P¼0.015) in the association (Fisher’s exact
P¼0.041) between CMV viremia and HHV6 viral load group:
3 patients with CMV viremia were in the low HHV 6 viral
load group versus 1 patient in the high group. Five of the
fourteen patients died (one of whom relapsed), suggesting a
high non-relapse mortality rate (28%) in this population.
Conclusion: End-organ disease/dysfunction with HHV6
positivity can persist despite a decrease in peripheral viral
load after antiviral treatment. Further studies will elucidate
whether prolonged or intensive antiviral treatment is war-
ranted in such cases.
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